Antibody-Drug Conjugate (ADC) combines the high specificity of antibody drugs and the powerful cancer cell killing effect of chemotherapy drugs, which can improve the shortcomings of traditional small molecule chemotherapy drugs in non-specific action, and make the poisonous substances act on tumor cells. , so the curative effect of the treatment of cancer is better, attracting the global market to invest in development. The antibody-drug linking technology of ADC has gradually matured after years of development. However, there are still many problems of drug heterogeneity, which cannot effectively and uniformly bind small molecule drugs to fixed binding sites, so that the stability of ADC drugs cannot be improved.

1. Tri-mannosyl-ADC technology is the position where the drug is combined with this sugar group to form a specific conjugated drug, forming a homogeneous antibody drug conjugate (ADC), which makes the quality of the ADC more specific and stable.
2. Tri-mannosyl-ADC platform drug connection method has diversity, DAR (drug antibody ratio) can be 2 or 4 homogeneity, when DAR is 4, the connecting drug can be single or two, so it can control drug toxicity and reduce resistance Medicinal advantages.
3. The drug linking reaction is in the aqueous phase at room temperature, which is easy to operate and has a high conversion rate.
4. Through fermentation and glycoengineering cell lines, a large amount of trimannose core homogeneous glycosyl antibodies and process conversion enzymes can be produced, and the production cost can be greatly reduced.